This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact...
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact...
This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact...
MedicalResearch.com Interview with: Prof. Hiddo Lambers Heerspink, PhD PHARMD Department of Clinical Pharmacy and Pharmacology University Medical Center Groningen Groningen
MedicalResearch.com: What is the background for this study? What is dapagliflozin primarily indicated for? Response: Dapagliflozin is a sodium glucose cotransporter 2 (SGLT2) inhibitor. The multinational, double-blinded, randomized, placebo-controlled, DAPA-CKD trial demonstrated the kidney and cardiovascular benefits of dapagliflozin in 4304 patients with chronic kidney disease (CKD) with and without type 2 diabetes (T2D). Based on the results of this and other trials, current guidelines recommend use of SGLT2 inhibitors in patients with CKD, T2D, or heart failure. Anemia is common among patients with CKD and is associated with worse clinical outcomes. Previous studies showed that SGLT2 inhibitors increase hemoglobin and hematocrit levels, but data are lacking in patients with CKD with and without T2D. In this post-hoc analysis of DAPA-CKD, we assessed the effect of dapagliflozin versus placebo on the correction and prevention of anemia in this population. (more…)Substance abuse is a serious problem that affects millions of people around the world. It can take many forms, from...
Statement from Dr. Robert Gabbay, Chief Scientific and Medical Officer for the ADA, regarding the Lilly statement this of April...